ATE113470T1 - Gehirnspezifische zubereitung mit gesteuerter abgabe. - Google Patents

Gehirnspezifische zubereitung mit gesteuerter abgabe.

Info

Publication number
ATE113470T1
ATE113470T1 AT90115389T AT90115389T ATE113470T1 AT E113470 T1 ATE113470 T1 AT E113470T1 AT 90115389 T AT90115389 T AT 90115389T AT 90115389 T AT90115389 T AT 90115389T AT E113470 T1 ATE113470 T1 AT E113470T1
Authority
AT
Austria
Prior art keywords
brain
controlled delivery
specific preparation
active substance
pharmaceutically active
Prior art date
Application number
AT90115389T
Other languages
English (en)
Inventor
Toru Hayakawa
Toshiki Yoshimine
Keiji Fujioka
Yoshihiro Takada
Yoshio Sasaki
Tsunemasa Irie
Nobuyuki Fukushima
Original Assignee
Sumitomo Pharma
Koken Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma, Koken Kk filed Critical Sumitomo Pharma
Application granted granted Critical
Publication of ATE113470T1 publication Critical patent/ATE113470T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT90115389T 1989-08-10 1990-08-10 Gehirnspezifische zubereitung mit gesteuerter abgabe. ATE113470T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20848489 1989-08-10

Publications (1)

Publication Number Publication Date
ATE113470T1 true ATE113470T1 (de) 1994-11-15

Family

ID=16556927

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90115389T ATE113470T1 (de) 1989-08-10 1990-08-10 Gehirnspezifische zubereitung mit gesteuerter abgabe.

Country Status (6)

Country Link
EP (1) EP0412554B1 (de)
JP (1) JP3187410B2 (de)
AT (1) ATE113470T1 (de)
DE (1) DE69013797T2 (de)
DK (1) DK0412554T3 (de)
ES (1) ES2066062T3 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69119759T2 (de) * 1990-03-20 1997-01-16 Amrad Corp Ltd Verfahren zur steuerung der neuronentwicklung und des neuronunterhalts
IT1240683B (it) * 1990-04-26 1993-12-17 Zambon Spa Composizione farmaceutica contenente egf
US6517859B1 (en) 1990-05-16 2003-02-11 Southern Research Institute Microcapsules for administration of neuroactive agents
DE69133136T2 (de) * 1990-05-16 2003-06-18 Southern Research Institute, Birmingham Mikrokapseln mit gesteuerter freigabe sowie deren verwendung zur stimulierung des nervenfaserwachstums
DE4019208A1 (de) * 1990-06-15 1992-03-05 Peter Dr Med Wehling Nervenregenerationsmittel
EP0578823B1 (de) * 1991-04-08 2002-01-23 Sumitomo Pharmaceuticals Company, Limited Poröse feste zubereitung, die eine physiologische aktive proteinverbindung enthält
WO1992020400A1 (en) * 1991-05-24 1992-11-26 Sumitomo Pharmaceuticals Company, Limited Instrument for applying pharmaceutical to inside of brain
IT1247472B (it) * 1991-05-31 1994-12-17 Fidia Spa Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
US5981165A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
DE4237047A1 (en) * 1991-11-04 1993-05-06 I N R O Handels-Gmbh, 8750 Aschaffenburg, De Drug contg. polypeptide homologous to nerve growth factor and slow virus sequence - for treating amyotrophic lateral sclerosis, spinal muscle atrophy or Parkinson's disease
US6451763B1 (en) 1992-06-04 2002-09-17 The United States Of America As Represented By The Department Of Health And Human Services Retinal pigmented epithelium derived neurotrophic factor and methods of use
WO1994006455A1 (en) * 1992-09-14 1994-03-31 Regeneron Pharmaceuticals, Inc. Method of producing analgesia using neurotrophins
US6998268B2 (en) 1995-07-03 2006-02-14 Dainippon Sumitomo Pharma Co. Ltd. Gene preparations
KR100431779B1 (ko) * 1995-07-03 2004-09-04 가부시끼가이샤 고껜 유전자제제
US5780027A (en) * 1995-07-14 1998-07-14 Meiogen Biotechnology Corporation Methods of treatment of down syndrome by interferon antagonists
AU708536B2 (en) * 1996-05-21 1999-08-05 Cytotherapeutics, Inc. System and method for delivery of cytokines using encapsulated cytokine-secreting cells
AU2001264317A1 (en) * 2000-06-20 2002-01-02 Koken Co., Ltd. Preparations for oligonucleotide transfer
EP1407787B1 (de) 2001-06-20 2009-04-29 Dainippon Sumitomo Pharma Co., Ltd. Verfahren zur förderung des nukleinsäuretransfers
CN108840924A (zh) * 2018-06-20 2018-11-20 罗国球 一种高蛋白含量脑蛋白水解物的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0139286B1 (de) * 1983-10-14 1991-08-21 Sumitomo Pharmaceuticals Company, Limited Verlängerte Präparate mit verzögerter Abgabe
CA1277601C (en) * 1985-12-27 1990-12-11 Shigeji Sato Method for producing sustained release formulation
US4832686A (en) * 1986-06-24 1989-05-23 Anderson Mark E Method for administering interleukin-2
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier

Also Published As

Publication number Publication date
EP0412554A3 (en) 1991-09-25
EP0412554B1 (de) 1994-11-02
DE69013797T2 (de) 1995-05-18
DE69013797D1 (de) 1994-12-08
DK0412554T3 (da) 1994-12-12
ES2066062T3 (es) 1995-03-01
JPH03163032A (ja) 1991-07-15
JP3187410B2 (ja) 2001-07-11
EP0412554A2 (de) 1991-02-13

Similar Documents

Publication Publication Date Title
DE69013797D1 (de) Gehirnspezifische Zubereitung mit gesteuerter Abgabe.
DE3779500D1 (de) Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
AU549481B2 (en) Hair growing agent
MX172600B (es) , "procedimiento para la produccion de una proteina biologicamente activa
ES2141706T3 (es) Formulaciones y su empleo en el tratamiento de enfermedades neurologicas.
AU4732989A (en) Pyrimidines and their pharmaceutical acceptable salts thereof, and their use as medicines
ATE185268T1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
ATE169219T1 (de) Behandlung von katarakt mit 15-keto- prostaglandinderivaten
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
DK360188D0 (da) Laegemiddelafgivelsesorgan
HU883863D0 (en) Process for the preparation of producing and/or portionly form of therapeutical agents
DE69130586D1 (de) Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten
NO883122D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive arylamid-derivater.
ATE38151T1 (de) Bestaendige 5-adenosyl-l-methionin-salze enthaltende, pharmazeutische zusammensetzungen fuer orale anwendung.
EP0424156A3 (en) Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
DE69032000D1 (de) Behandlung kardialer Dysfunktion mit 15-Ketoprostaglandinderivaten
DE69023459D1 (de) Behandlung von pulmonarer Disfunktion mit 15-Keto-prostaglandin-Derivaten.
KR900009029A (ko) 가축병 치료용 약물을 투여하는 장치
EP0454429A3 (en) Use of 15-dehydroxy-16-oxoprostaglandin derivatives in the treatment of allergic diseases
EP0193164A3 (de) 2-Nitroxymethyl-6-chloropyridin enthaltende Arzneipräparate mit verzögerter Freisetzung, Verfahren zu deren Herstellung sowie deren Verwendung
DE68901172D1 (de) (-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend.
NO875461D0 (no) Fremgangsmaate for fremstilling av et terapeutisk aktivt peptid.
DK15088D0 (da) Antibakterielt lyofiliseret praeparat
NO882282D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyrazin-amider.
KR890700374A (ko) 전신에 유효한 약품의 경피 전달용 붕대

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee